Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rolf Kiessling

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
The Journal of Clinical Investigation|January 20, 2016
TAP-ing into TIEPPs for cancer immunotherapyRolf Kiessling
Journal of Molecular Medicine (Berlin, Germany)|October 8, 2010
Designer lymphocytes to fight cancer: a helping hand from modern molecular biologyRolf Kiessling
Critical Reviews in Oncogenesis|September 10, 2014
Serendipity. Coincidence. LuckRolf Kiessling
Trends in Molecular Medicine|September 17, 2013
The two sides of HER2/neu: immune escape versus surveillanceBarbara Seliger, Rolf Kiessling
Clinical Immunology (Orlando, Fla.)|August 4, 2012
On the armament and appearances of human myeloid-derived suppressor cellsIsabel Poschke, Rolf Kiessling
Cancer Immunology, Immunotherapy : CII|June 1, 2011
Camouflage and sabotage: tumor escape from the immune systemIsabel Poschke, Dimitrios Mougiakakos, Rolf Kiessling
Blood|December 4, 2008
Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell deathDimitrios Mougiakakos, C Christian Johansson, Rolf Kiessling
Lakartidningen|October 4, 2008
[Therapeutic vaccines against cancer and infectious diseases. Great possibilities in the research--small clinical progress so far]Rolf Kiessling, Karl Ljungberg, Alexander Von Gabain
Trends in Molecular Medicine|June 21, 2015
Checkpoint blockade for cancer therapy: revitalizing a suppressed immune systemYago Pico de Coaña, Aniruddha Choudhury, Rolf Kiessling
Cancer Immunology, Immunotherapy : CII|April 10, 2002
Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L)Andreas Lundqvist, Takako Nagata, Rolf Kiessling, et al.
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
The Journal of Clinical Investigation|January 20, 2016
TAP-ing into TIEPPs for cancer immunotherapyRolf Kiessling
Journal of Molecular Medicine (Berlin, Germany)|October 8, 2010
Designer lymphocytes to fight cancer: a helping hand from modern molecular biologyRolf Kiessling
Critical Reviews in Oncogenesis|September 10, 2014
Serendipity. Coincidence. LuckRolf Kiessling
Trends in Molecular Medicine|September 17, 2013
The two sides of HER2/neu: immune escape versus surveillanceBarbara Seliger, Rolf Kiessling
Clinical Immunology (Orlando, Fla.)|August 4, 2012
On the armament and appearances of human myeloid-derived suppressor cellsIsabel Poschke, Rolf Kiessling
Cancer Immunology, Immunotherapy : CII|June 1, 2011
Camouflage and sabotage: tumor escape from the immune systemIsabel Poschke, Dimitrios Mougiakakos, Rolf Kiessling
Blood|December 4, 2008
Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell deathDimitrios Mougiakakos, C Christian Johansson, Rolf Kiessling
Lakartidningen|October 4, 2008
[Therapeutic vaccines against cancer and infectious diseases. Great possibilities in the research--small clinical progress so far]Rolf Kiessling, Karl Ljungberg, Alexander Von Gabain
Trends in Molecular Medicine|June 21, 2015
Checkpoint blockade for cancer therapy: revitalizing a suppressed immune systemYago Pico de Coaña, Aniruddha Choudhury, Rolf Kiessling
Cancer Immunology, Immunotherapy : CII|April 10, 2002
Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L)Andreas Lundqvist, Takako Nagata, Rolf Kiessling, et al.
Pageof 14